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ABSTRACT
Objective: Ursodeoxycholic acid (UDCA) exerts anti-
cholestatic effects in part by protein kinase C (PKC)-
dependent mechanisms. Its taurine conjugate, TUDCA, is
a cPKCa agonist. We tested whether protein kinase A
(PKA) might contribute to the anticholestatic action of
TUDCA via cooperative cPKCa-/PKA-dependent mechan-
isms in taurolithocholic acid (TLCA)-induced cholestasis.
Methods: In perfused rat liver, bile flow was determined
gravimetrically, organic anion secretion spectrophotome-
trically, lactate dehydrogenase (LDH) release enzymati-
cally, cAMP response-element binding protein (CREB)
phosphorylation by immunoblotting, and cAMP by
immunoassay. PKC/PKA inhibitors were tested radio-
chemically. In vitro phosphorylation of the conjugate
export pump, Mrp2/Abcc2, was studied in rat hepato-
cytes and human Hep-G2 hepatoma cells.
Results: In livers treated with TLCA (10 mmol/l)+TUDCA
(25 mmol/l), combined inhibition of cPKC by the cPKC-
selective inhibitor Go¨6976 (100 nmol/l) or the non-
selective PKC inhibitor staurosporine (10 nmol/l) and of
PKA by H89 (100 nmol/l) reduced bile flow by 36%
(p,0.05) and 48% (p,0.01), and secretion of the Mrp2/
Abcc2 substrate, 2,4-dinitrophenyl-S-glutathione, by 31%
(p,0.05) and 41% (p,0.01), respectively; bile flow was
unaffected in control livers or livers treated with TUDCA
only or TLCA+taurocholic acid. Inhibition of cPKC or PKA
alone did not affect the anticholestatic action of TUDCA.
Hepatic cAMP levels and CREB phosphorylation as
readout of PKA activity were unaffected by the bile acids
tested, suggesting a permissive effect of PKA for the
anticholestatic action of TUDCA. Rat and human
hepatocellular Mrp2 were phosphorylated by phorbol
ester pretreatment and recombinant cPKCa, nPKCe, and
PKA, respectively, in a staurosporine-sensitive manner.
Conclusion: UDCA conjugates exert their anticholestatic
action in bile acid-induced cholestasis in part via
cooperative post-translational cPKCa-/PKA-dependent
mechanisms. Hepatocellular Mrp2 may be one target of
bile acid-induced kinase activation.
Ursodeoxycholic acid (UDCA) has been used for
the treatment of jaundice in Chinese traditional
medicine since the Tang dynasty (618–907 AD) in
the form of dried black bear’s bile. Today, UDCA
represents the only drug approved by the US Food
and Drug Administration for the treatment of
primary biliary cirrhosis (PBC), a model cholestatic
liver disease.1 UDCA improves biliary secretion in
PBC and a number of other cholestatic disorders,
such as primary sclerosing cholangitis (PSC) or
intrahepatic cholestasis of pregnancy (ICP).2 In
early-stage PBC, UDCA delays progression to
cirrhosis3 4 as well as development of complica-
tions,5 and normalises life expectancy.6–8 Several
mechanisms of action of UDCA have been
discussed, and stimulation of impaired hepatobili-
ary secretion, detoxification of bile, and anti-
apoptotic effects are assumed to contribute to the
beneficial effect of UDCA in cholestatic disorders.9
UDCA conjugates, such as tauroursodeoxycholic
acid (TUDCA), are potent signalling molecules both
in hepatocytes and cholangiocytes.9 10 In hepato-
cytes, TUDCA has been shown to induce increases
of cytosolic free calcium [Ca2+]i and Ca
2+ influx,11–13
to selectively activate Ca2+-dependent conventional
protein kinase Ca (cPKCa),14 15 to stimulate an
integrin-dependent dual signalling pathway leading
to activation of mitogen-activated protein kinases
(MAPKs), Erk1/2 and p38MAPK,16–19 and to induce
targeting and insertion of key apical transporters like
the bile salt export pump, Bsep/Abcb11, and the
conjugate export pump, Mrp2/Abcc2, into canali-
cular membranes of hepatocytes.17 20 21 In normal
hepatocytes, MAPK-dependent mechanisms med-
iate, in part, the choleretic effect of TUDCA,16 17
whereas in experimental cholestasis, PKC-dependent
mechanisms appear to contribute to the antichole-
static action of TUDCA.20 22
Taurolithocholic acid (TLCA) is the most potent
cholestatic agent among the major human bile
acids23 and has recently been shown to exert its
cholestatic action at the hepatocyte level by
phosphatidylinositol-3-kinase, and putatively
nPKCe-dependent mechanisms in isolated perfused
rat livers (IPRLs) and isolated rat hepatocyte
couplets.24 Like TUDCA, TLCA is a potent signal-
ling molecule which elevates hepatocellular [Ca2+]i
without stimulation of Ca2+ influx,25 selectively
translocates nPKCe to canalicular membranes and
activates membrane-bound PKC,26 and induces
retrieval of key apical transporters such as the bile
salt export pump, Bsep/Abcb11, from canalicular
membranes of hepatocytes.21
Direct effects of bile acids such as TLCA or
TUDCA on PKA activity in hepatocytes have not
been disclosed although glucagon-induced cAMP
formation was impaired by TUDCA in a stauro-
sporine-sensitive fashion in hamster hepatocytes.27
PKC agonists at moderate concentrations and PKA
are known to stimulate liver cell secretion.10 A
cooperative PKC-/PKA-dependent mechanism has
recently been described to potentiate chloride
secretion via the Xenopus cystic fibrosis transmem-
brane conductance regulator, XCFTR,28 in Xenopus
oocytes, and concomitant activation of cPKCa and
PKA led to marked stimulation of insulin secretion
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in pancreatic beta cells by a convergent mechanism.29 Therefore,
we tested the hypothesis that TUDCA may exert anticholestatic
effects in the well-established model of TLCA-induced cholestasis
by a cooperative cPKCa-/PKA-dependent mechanism.
MATERIALS AND METHODS
Materials
Bile acids and dimethylsulfoxide (DMSO) were purchased from
Sigma (St. Louis, Missouri, USA). 1-Chloro-2,4-dinitrobenzene
(CDNB) was from ICN Biomedicals (Aurora, Ohio, USA). The
nonselective PKC inhibitor stauroporine (ST), the cPKC inhibitor
Go¨6976, the PKA inhibitor H89, and the recombinant catalytic
subunits of cPKCa, nPKCe and PKA were from Calbiochem–
Novabiochem (Nottingham, UK). The anti-MRP2/ABCC2 anti-
body was from Alexis (Lausen, Switzerland). A rabbit anti-pCREB
antibody and a monoclonal CREB antibody were from Cell
Signalling (Danvers,Massachusetts,USA),andamonoclonalmouse
anti-GAPDH antibody was from Abcam (Cambridge, UK). A goat-
anti-rabbit-IgG-HRP-conjugate-antibody was from Bio-Rad Lab
(Munich, Germany) and a goat-anti-mouse-IgG-HRP antibody was
from Santa Cruz Biotechnology (Santa Cruz, California, USA).
Complete protease inhibitor cocktail was from Roche Diagnostics
(Mannheim, Germany). Marker molecular weight standard was
from Santa Cruz Biotechnology. The Renaissance western blot
chemiluminescencereagentwas fromNEN(Boston,Massachusetts,
USA). Hyperfilm ECL was from Amersham (Little Chalfont, UK).
Polyvinylidene difluoride membranes were from Millipore (Bedford,
Massachusetts, USA). A cAMP enzyme immunoassay kit was from
Amersham Biosciences (Freiburg, Germany). FosCholin-12 was
from Anatrace (Maumee, Ohio, USA). Protein A-Sepharose was
from Zymed (San Francisco, California, USA). All other chemicals
were of the highest purity commercially available.
Protein kinase inhibitors
The effect of inhibitors on activity of cPKCa, nPKCe, and PKA was
tested in vitro at levels at least 5- to 10-fold above their IC50 for
cPKCa, as indicated in the literature, using myelin basic protein
(MBP) as substrate to apply concentrations in the IPRLs high
enough to be effective, but not too high to cause cholestatic effects.
The results showed that cPKCa was more effectively blocked by
the nonselective PKC inhibitor staurosporine (10 nmol/l) than by
the cPKC-specific inhibitor Go¨6976 (10–100 nmol/l) (table 1).
nPKCe was inhibited by staurosporine (10 nmol/l), but not by
Go¨6976 (10–100 nmol/l). In addition, the selective PKA inhibitor,
H89 (100 nmol/l), and staurosporine (10 nmol/l), but not Go¨6976
blocked PKA effectively (table 1).
Animals
Male Sprague–Dawley rats (208 (SD 22) g) were obtained from
Charles River (Sulzfeld, Germany) and were subjected to a 12 h
day–night rhythm with free access to rodent chow and water.
Isolated rat liver perfusions were performed as described in
detail previously.20 24 Bile flow was determined gravimetrically
in pretared tubes.
Perfusion protocol
Rat livers were perfused for a total of 115 min in a non-
recirculating fashion with Krebs–Ringer bicarbonate solution
(pH 7.4, 37uC). Twenty-five minutes after starting the perfusion,
the nonselective PKC inhibitor staurosporine (final concentration
in the portal vein, 10 nmol/l), the cPKC inhibitor Go¨6976
(100 nmol/l), and/or the PKA inhibitor H89 (100 nmol/l) were
infused continuously into the perfusion medium. Forty-five
minutes after start of the perfusion, bile acids (TUDCA, TLCA,
TCA, TUDCA+TLCA, TCA+TLCA), dibutyryl cAMP (dbcAMP)
or the carrier DMSO only (control, 0.1%, v/v) were added
continuously to the buffer by using an infusion pump to reach
Table 1 Effect of the protein kinase C (PKC) inhibitors staurosporine (ST, 10 nmol/l) and Go¨6976 (100 nmol/l),
and the PKA inhibitor H89 (100 nmol/l) on activity of recombinant cPKCa, nPKCe and PKA in vitro using myelin
basic protein as kinase substrate
cPKCa nPKCe PKA
Inhibitor
Concentration
(nmol/min/g) %
Concentration
(nmol/min/g) %
Concentration
(pmol/min/mU) %
H2O standard 309 (74) 100 77 100 4.4 (1.7) 100
DMSO control 294 (46) 96 71 (11) 96 4.7 (1.6) 111
ST 23 (3)** 8 7 (1)** 9 1.0 (0.6)* 22
Go¨6976 163 (52) 53 61 (10) 82 4.2 (1.5) 98
H89 217 (53) 71 44 (8) 58 0.2 (0.1)** 5
ST+H89 23 (4)** 8 6 (1)** 8 0.1 (0.1)** 2
Go¨6976+H89 107 (20)** 35 44 (5) 60 0.4 (0.2)** 10
PKC and PKA inhibitors were tested at concentrations at least 5- to 10-fold above their elsewhere reported IC50 for cPKCa and PKA,
respectively, at which they did not affect bile flow and organic anion secretion in isolated perfused rat livers. For details see
Materials and methods. Results are given as mean (SD) of protein kinase activity of four independent experiments (% of H2O
standard).
*p,0.05, **p,0.01 vs DMSO control (0.1%,v/v), ANOVA post hoc test (Tukey).
DMSO, dimethylsulfoxide.
Table 2 cAMP levels and protein kinase A (PKA) activity in liver tissue
are not affected by the bile acids taurolithocholic acid (TLCA) and
tauroursodeoxycholic acid (TUDCA)
Bile acid Inhibitor cAMP (pmol/g liver) pCREB (AE)
DMSO 30.6 (3.5) 0.52 (0.07)
DMSO ST+H89 30.1 (10.6) 0.25 (0.04)**
TUDCA 24.9 (7.7) 0.37 (0.15)
TUDCA ST+H89 29.6 (7.4) 0.26 (0.11)
TLCA 30.8 (8.7) 0.34 (0.11)
TLCA ST+H89 36.6 (3.3) 0.22 (0.07)
TLCA+TUDCA 31.7 (6.5) 0.36 (0.22)
TLCA+TUDCA ST+H89 39.5 (14.0) 0.32 (0.14)
cAMP levels and phosphorylated cAMP response-element binding protein (pCREB) levels
as a readout of PKA activity were determined with an enzyme-linked immunosorbent
assay and by immunoblotting, respectively, in shock-frozen liver tissue after perfusion
with the bile acids TLCA (10 mmol/l) and/or TUDCA (25 mmol/l) or their carrier, dimethyl
sulfoxide (DMSO; 0.1%, v/v) in the presence or absence of the potent PKC inhibitor
staurosporine (ST, 10 nmol/l) and the PKA inhibitor H89 (100 nmol/l; see fig 1 and
table 1). Significant reduction of pCREB, but not cAMP in the presence of H89 in control
livers depicts the specificity of action of this PKA inhibitor. For details, see Materials and
methods. Mean (SD) of four to five experiments, each.
**p,0.001 vs inhibitor-free perfusion; Student t test.
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final portal venous concentrations of 25 mmol/l (TUDCA, TCA)
or 10 mmol/l (TLCA, dbcAMP). Sixty-five minutes after start of
the perfusion, 1-chloro-2,4-dinitrobenzene (CDNB; 30 mmol/l),
the precursor of the model Mrp2/Abcc2 substrate, 2,4-dinitro-
phenyl-S-glutathione (GS-DNP), was infused for 10 min. At this
concentration, saturation of the biliary GS-DNP secretion was
observed in the perfused rat liver.20
Biliary secretion of 2,4-dinitrophenyl-S-glutathione
The model Mrp2/Abcc2 substrate, GS-DNP, was determined in
bile spectrophotometrically as described previously.20
Hepatovenous efflux of lactate dehydrogenase
Lactate dehydrogenase (LDH) was determined as an indicator of
liver cell damage in the hepatovenous effluate by use of a
standard enzymatic test.20
cAMP in liver tissue
cAMP was extracted from liver tissue with a liquid phase
extraction method conforming to the supplier’s protocol and
was determined by an enzyme immunoassay.
pCREB in liver tissue
An aliquot of shock-frozen liver tissue (280uC) was homogenised,
and proteins were separated by western blotting. pCREB and
GAPDH were identified by use of specific antibodies. pCREB and
GAPDH were semiquantified by densitometry and pCREB was
expressed as a ratio pCREB/GAPDH.
Rat hepatocyte isolation and in vitro phosphorylation of Mrp2/
Abcc2
Rat hepatocytes were isolated and cultured on collagen-coated
wells as described previously.30 A sample of 56106cells/well was
incubated for 2 h after plating for 4 h with 32P-orthophosphoric
acid (74 MBq) and were then treated for 30 min with DMSO
(0.1%, v/v), 100 nmol/l phorbol 12-myristate 13-acetate (PMA),
100 nmol/l PMA + 10 nmol/l staurosporine, 25 mmol/l TUDCA,
or 10 mmol/l TLCA. Cells were then washed three times with
phosphate-buffered saline (PBS).
Immunoprecipitation of rat Mrp2/Abcc2 or human MRP2/ABCC2
Rat Mrp2/Abcc2 and human MRP2/ABCC2 were immunopre-
cipitated from rat hepatocytes and human HepG2 hepatoma
cells, respectively, as published previously.31 Efficacy of Mrp2/
Abcc2 immunoprecipitation was tested by western blotting.
Phosphorylation of human MRP2/ABCC2 in vitro
Phosphorylation was peformed using a phosphorylation buffer
containing 10 mmol/l ATP and per sample 370 kBq [c32]ATP,
and 400 U activated PKA or 90 ng activated cPKCa or/and
110 ng activated nPKCe. MBP was used as a phosphorylation
control. Samples were immunoblotted and autoradiography of
the gels was performed for 18 h. The bands corresponding to
32P-MRP2/ABCC2 were excised and radioactivity was counted
in a scintillation counter.
Statistics
Data are expressed as mean (SD). Results were compared
between different groups using ANOVA post hoc test (Tukey).
Comparison of two groups only was performed using an
unpaired two-tailed Student t test. A value of p,0.05 was
considered statistically significant.
RESULTS
Bile flow
TLCA (10 mmol/l) reduced bile flow in isolated perfused rat
livers (IPRLs) to 14% of controls (figs 1A,B and 2A). TUDCA
(25 mmol/l) reversed TLCA-induced inhibition of bile flow to
173% of controls. The nonselective PKC inhibitor staurosporine
(10 nmol/l), the selective cPKC inhibitor Go¨6976 (100 nmol/l),
and the selective PKA inhibitor H89 (100 nmol/l) did not
significantly affect bile flow in either control livers or in livers
treated with TLCA+TUDCA (figs 1A,B and 2A). In contrast,
when administered concomitantly, staurosporine+H89 as well
as Go¨6976+H89 induced a significant reduction of bile flow in
livers treated with TLCA+TUDCA by 48% (p,0.01) and 36%
(p,0.05), respectively, but again, did not affect bile flow in
controls or livers treated with TUDCA only (figs 1A–C and 2A).
The cAMP analogue, dibutyryl cAMP (dbcAMP, 10 mmol/l),
stimulated bile flow in controls by 55% (p,0.01), but did not
significantly enhance bile flow in livers treated with TLCA (+81%,
NS) or TLCA+TUDCA (+16%, NS) indicating that stimulation of
PKA only does not reverse TLCA-induced cholestasis in IPRL.
The taurine conjugate of the major human trihydroxy bile
acid, cholic acid (TCA, 25 mmol/l) also reverses TLCA-induced
inhibition of bile flow in rat liver.32 Unlike TUDCA, TCA does
not affect hepatocellular [Ca2+]i and PKC isoform distribution at
physiological concentrations.11 14 Indeed, reversal of TLCA-
induced inhibition of bile flow by TCA was not affected by
staurosporine+H89 (fig 2A) suggesting different molecular
mechanisms mediating the anticholestatic action of TUDCA
and TCA in TLCA-induced cholestasis.
Together, these data suggest that recovery of bile flow by
TUDCA in TLCA-induced cholestasis – but not stimulation of
bile flow under non-cholestatic conditions – is mediated by a
cooperative cPKC-/PKA-dependent mechanism.
Secretion of 2,4-dinitrophenyl-S-glutathione
TLCA reduced biliary secretion of the Mrp2/Abcc2 substrate,
2,4-dinitrophenyl-S-glutathione (GS-DNP), to 7% of controls.
TUDCA reversed TLCA-induced inhibition of biliary GS-DNP
secretion to 113% of controls (fig 2B). The nonselective PKC
inhibitor staurosporine impaired biliary GS-DNP secretion by
32% (p,0.05) and the cPKC inhibitor Go¨6976 tended to impair
biliary GS-DNP secretion by 24% in livers treated with
TLCA+TUDCA (fig 2B), but not in control livers. The PKA
inhibitor H89 did not affect biliary GS-DNP secretion in livers
treated with TLCA+TUDCA (fig 2B) when given alone. When
administered concomitantly, staurosporine+H89 as well as
Go¨6976+H89 reduced biliary GS-DNP secretion by 41%
(p,0.01) and 31% (p,0.05), respectively, in livers treated with
TLCA + TUDCA. In contrast, biliary GS-DNP secretion in
controls or livers treated with TUDCA only was barely affected
by PKC/PKA inhibitors (fig 2B). Biliary GS-DNP secretion was
not further enhanced by the cAMP analogue, dbcAMP, in
controls, livers treated with TLCA or livers treated with
TLCA+TUDCA (25.7%, +1.6%, and 249%, respectively).
Together, these data indicate that TUDCA-induced recovery
of organic anion secretion via Mrp2/Abcc2 is mediated by a
cooperative cPKC-/PKA-dependent mechanism in TLCA-
induced cholestasis.
Hepatic cAMP levels and PKA activity
Hepatic cAMP levels were unaffected by any of the bile acids
and inhibitors of PKC and PKA tested (table 2). In addition,
CREB phosphorylation as a readout of PKA activity in liver
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tissue was unaffected by the bile acids used (table 2) suggesting
that PKA activity, in line with previous findings,10 27 is rather
permissive for the anticholestatic action of TUDCA.
Hepatovenous LDH release
The cholestatic effect of TLCA is associated with a serious
cytotoxic action as demonstrated by a 32-fold increase of
hepatovenous LDH release as a readout of liver cell damage.
TLCA-induced LDH release was attenuated by addition of
TUDCA, but markedly increased after combined inhibition of
PKC and PKA in livers treated with TLCA+TUDCA – but not
after inhibition of either PKC or PKA alone – in parallel with the
inhibition of the anticholestatic action of TUDCA (table 3). In
contrast, LDH release was unaffected by combined inhibition of
PKC and PKA in controls and livers treated with TUDCA or
Figure 1 Bile flow is stimulated by
tauroursodeoxycholic acid (TUDCA) via a
cooperative c protein kinase C/protein
kinase A (cPKC-/PKA)-dependent
mechanism in taurolithocholic acid
(TLCA)-induced cholestasis, but not under
control conditions. (A) Bile flow was
markedly impaired by TLCA (10 mmol/l) in
isolated perfused rat livers. TUDCA
(25 mmol/l) reversed TLCA-induced
cholestasis. The nonselective PKC
antagonist staurosporine (10 nmol/l), but
not the selective PKA inhibitor H89
(100 nmol/l), when given alone, tended to
impair the anticholestatic effect of TUDCA
whereas combined administration of
staurosporine and the selective PKA
inhibitor H89 (100 nmol/l) significantly
impaired the anticholestatic effect of
TUDCA. (B) The selective cPKC inhibitor
Go¨6976 (100 nmol/l), when given alone,
did not impair the anticholestatic effect of
TUDCA in TLCA-induced cholestasis.
Combined administration of Go¨6976 and
H89 led to a significant impairment of the
anticholestatic effect of TUDCA in TLCA-
induced cholestasis. (C) Combined
administration of the nonselective PKC
inhibitor staurosporine (10 nmol/l) and
the PKA inhibitor, H89 (100 nmol/l), did
neither affect bile flow of DMSO controls
nor of livers treated with TUDCA or TLCA
alone (see also fig 2). All results are given
as means (SD) of four to five
experiments, each. For statistical
evaluation, see fig 2. Results for TLCA in
panels B and C, and for TLCA + TUDCA in
panel B are identical to those in panel A
and are provided for clarity.
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TLCA alone (table 3). These data suggest that TUDCA
alleviates TLCA-induced liver cell damage in part by a
cooperative cPKCa-/PKA-dependent mechanism in association
with its anticholestatic action.
Phosphorylation of rat Mrp2 by the nonselective PKC agonist,
phorbol 12-myristate 13-acetate
Rat Mrp2 was immunoprecipitated from freshly isolated rat
hepatocytes in short-term culture after incubation of hepatocytes
with 32P-orthophosphoric acid for 4 h and with DMSO (0.1%),
PMA (100 nmol/l), PMA+staurosporine (10 nmol/l), TUDCA
(25 mmol/l), and TLCA (10 mmol/l) for 30 min. The results show
that Mrp2 was phosphorylated under control conditions. The
PMA-induced increase in phosphorylation was reversed by
staurosporine. Bile acids at low micromolar concentrations did
not affect total phosphorylation of Mrp2 (fig 3A).
Phosphorylation of human MRP2 by cPKCa, nPKCe and PKA
Human MRP233 was immunoprecipitated from HepG2 hepa-
toma cells and MRP2 phosphorylation was studied in vitro
using recombinant activated PKCa, PKCe or PKA. The results
show that the MRP2 complex after immunoprecipitation was
phosphorylated by cPKCa, nPKCe and PKA (fig 3B). Combined
incubation with cPKCa and nPKCe tended to induce a more
pronounced phosphorylation than incubation with cPKCa or
nPKCe alone in line with the assumption that different PKC
isoforms induce phosphorylation of the MRP2 complex at
different sites.
DISCUSSION
The present study demonstrates that the short-term anti-
cholestatic effect of TUDCA in the established experimental
model of TLCA-induced cholestasis is mediated mainly by a
cooperative cPKCa-/PKA-dependent mechanism.
We and others have previously observed that TUDCA at low
micromolar concentrations stimulates Ca2+ entry into hepato-
cytes independent of inositol-1,4,5-trisphosphate,11–13 selectively
translocates Ca2+-dependent cPKCa to hepatocyte mem-
branes,14 20 34 stimulates formation of s,n-1,2-diacylglycerol
(DAG),14 activates membrane-bound PKC14 34 and stimulates
impaired biliary secretion of organic anions and bile acids in
TLCA-induced cholestasis by PKC-dependent mechanisms in
isolated perfused rat liver (IPRL)20 and isolated rat hepatocyte
couplets,22 respectively. Similar effects of TUDCA on [Ca2+]i and
Ca2+-dependent cPKCa have been observed in cholangiocytes.35
The present study not only confirms a role of PKC, but, by use
of the cPKC-specific inhibitor Go¨6976 (figs 1B and 2A,B),
specifically shows that a Ca2+-dependent PKC isoform mediates
the anticholestatic effect of TUDCA. Among the known cPKC
isoforms, cPKCa, cPKCb-I, cPKCb-II and cPKCc, only cPKCa
and cPKCb-II have been detected in hepatocytes. We were not
able to disclose translocation of cPKCb-II by TUDCA to
hepatocyte membranes in IPRL, IRHC and Ntcp-transfected
HepG2 hepatoma cells (data not shown; see also Beuers et al14).
Thus, cPKCa is most likely the PKC isoform involved in the
anticholestatic action of TUDCA in experimental cholestasis as
suggested previously.14 20 36
Figure 2 Bile flow and organic anion secretion are stimulated by
tauroursodeoxycholic acid (TUDCA) via a cooperative c protein kinase
C-/protein kinase A (cPKC-/PKA)-dependent mechanism in
taurolithocholic acid (TLCA)-induced cholestasis. (A) Total bile flow
during the last 50 min after addition of inhibitors, the bile acids, TLCA,
TUDCA and cholic acid (TCA), and the 2,4-dinitro-S-glutathione (GS-DNP)
precursor, 1-chloro-2,4-dinitrobenzene (CDNB), for the experiments
shown in fig 1A,B. (B) Biliary GS-DNP secretion during the last 50 min
after addition of inhibitors, the bile acids, TLCA, TUDCA and TCA, and the
GS-DNP precursor CDNB. All results are given as means (SD) of four to
five experiments, each.*p,0.05, **p,0.01, ANOVA post hoc test.
Table 3 The cytoprotective effect of tauroursodeoxycholic acid in
taurolithocholic acid-induced cholestasis is impaired by combined
inhibition of c protein kinase C and protein kinase A
LDH release
Bile acid Inhibitor Concentration (mU/min/g liver) % of controls
DMSO 2.3 (1.2) 100
DMSO ST+H89 4.0 (5.1) 173
TUDCA 11.4 (4.4) 100
TUDCA ST+H89 11.7 (6.8) 103
TLCA 73.1 (31.7) 100
TLCA ST+H89 61.3 (29.3) 84
TLCA+TUDCA 21.3 (7.3) 100
TLCA+TUDCA ST 71.8 (34.2) 336
TLCA+TUDCA Go¨6976 40.5 (43.3) 190
TLCA+TUDCA H89 39.3 (7.2) 184
TLCA+TUDCA ST+H89 95.3 (24.7)* 446
TLCA+TUDCA Go¨6976+H89 64.1 (53.5) 300
TLCA+TCA 2.4 (5.3) 100
TLCA+TCA ST+H89 65.3 (52.0) 292
Hepatovenous lactate dehydrogenase (LDH) release as a readout of hepatocellular
damage was determined during steady state at 85 min in perfused rat livers after
addition of the bile acids TLCA (10 mmol/l), TUDCA (25 mmol/l), cholic acid (TCA;
25 mmol/l), the nonselective PKC inhibitor staurosporine (ST; 10 nmol/l), the selective
cPKC inhibitor Go¨6976 (100 nmol/l), and/or the selective PKA inhibitor H89 (100 nmol/l)
(see also fig 1). Results are given as mean (SD) of four to five experiments, each.
Experiments with inhibitors are also given as % of respective inhibitor-free controls
(100%).
*p,0.05 vs respective bile acid control, ANOVA post hoc test.
DMSO, dimethylsulfoxide.
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A role of cPKCa as a mediator of the choleretic effect of
TUDCA in IPRL was recently questioned and the cPKC agonist
thymeleatoxin was shown to induce cholestasis in IPRL.37 In
contrast to thymeleatoxin, TUDCA interacts with various
hepatocellular (and cholangiocellular) signalling cascades.9 Their
impact on control of diverse liver cell functions by TUDCA in
health and under cholestatic conditions remains to be further
unravelled. Our previous data were in line with the assumption
that bile flow and organic anion secretion under normal ‘‘non-
cholestatic’’ conditions are modulated by TUDCA mostly
independent of Ca2+ and Ca2+-dependent cPKCa (fig 1C; see
also Beuers et al12) whereas Ca2+-dependent cPKCa appears to
play a key role in the anticholestatic action of TUDCA in
TLCA-induced cholestasis.20
A relevant effect of TUDCA on hepatocellular PKA activity
has not been observed15 although PKA is a well-known mediator
of apical secretion in hepatocytes.38 In line with previous
findings, we were unable to observe an effect of TUDCA on
cAMP levels and PKA activity as reflected by unchanged CREB
phosphorylation in liver tissue. In addition, the selective PKA
inhibitor H89 alone did not affect TUDCA-induced bile
secretion in IPRL in the present study. It should be kept in
mind, however, that global determination of CREB phosphor-
ylation and cAMP in liver tissue may trivialise the complexity of
PKA action and cAMP signals in microdomains of the apical
plasma membrane.39 This assumption is strengthened by the
recent finding that type II inositol-1,4,5-trisphosphate receptor
(InsP3) isoforms are concentrated in the pericanalicular region
in a lipid raft-dependent way.40 41 Type II InsP3 are essential for
hepatocellular Ca2+ wave formation and, possibly, Ca2+/cPKCa/
PKA interaction. Thus, more sophisticated methodological
approaches will be needed to further elucidate the possibly
permissive role of PKA in the anticholestatic action of TUDCA
in the pericanalicular zone of hepatocytes.9
Under non-cholestatic conditions, an integrin-dependent dual
signalling pathway involving the MAPK Erk1/2 and p38MAPK
plays a role in mediating the choleretic effect of TUDCA in
IPRL.16–19 We were not able to show a role of MAPK for the
anticholestatic action of TUDCA in TLCA-induced cholestasis
when either Erk1/2 or p38MAPK or Erk1/2 and p38MAPK
concomitantly were inhibited.30 Thus, different signalling path-
ways mediate the choleretic and the anticholestatic action of
TUDCA in hepatocytes.9
A cooperative stimulation of secretory activity by PKC/PKA
as assumed in the present model for the anticholestatic action of
TUDCA has previously been described in different cell types.28 29
Apical carriers and their anchoring proteins42 43 are potential
targets of a concerted action of PKA and cPKCa at the
canalicular hepatocyte membrane for TUDCA-induced carrier
insertion as well as of nPKCe in TLCA-induced carrier retrieval.9
The deduced amino acid sequences of the conjugate and bile salt
export pumps, Mrp2/Abcc2 and Bsep/Abcb11, respectively,
show numerous potential serine/threonine phosphorylation
sites for PKC and PKA. We found that Mrp2/Abcc2 can be
phosphorylated in vitro in rat hepatocytes by PKC agonists or
after immunoprecipitation from HepG2 hepatoma cells by
recombinant activated cPKCa, nPKCe, and PKA. Interestingly,
Mrp2/Abcc2 transport activity has recently been shown to be
stimulated by cPKCa in a baculovirus coexpression system in
vitro.44 These findings are in line with those previously observed
for Bsep/Abcb1131 which also can be phosphorylated by cPKCa.
Identification of key serine/threonine phosphorylation sites
required for apical insertion and retrieval of Mrp2/Abcc2 or
BSEP/ABCB11 – as demonstrated for the sodium taurocholate
cotransporting polypeptide, Ntcp/Slc10a1, in the basolateral
membrane45 – will be a prerequisite to further unravel the
cholestatic and anticholestatic post-translational effects of bile
acids in hepatocytes.
In conclusion, the well-known anticholestatic effect of
TUDCA is largely blocked by selective pharmacological inter-
vention in the present study, indicating that TUDCA exerts its
Figure 3 The conjugate export pump, Mrp2/Abcc2, is phosphorylated
by protein kinase C (PKC) and protein kinase A (PKA) in a staurosporine-
sensitive way. (A) Rat hepatocyte total Mrp2/Abcc2 phosphorylation
was stimulated by phorbol 12-myristate 13-acetate (PMA), in a
staurosporine-sensitive way, but not by bile acids at low micromolar
concentrations. Rat hepatocytes were preloaded with 32P-
orthophosphoric acid and then treated for 4 h with dimethyl sulfoxide
(DMSO) (0.1%, v/v), 100 nmol/l PMA, 100 nmol/l PMA + 10 nmol/l
staurosporine, 25 mmol/l tauroursodeoxycholic acid (TUDCA) or
10 mmol/l taurolithocholic acid (TLCA). Cells were then homogenised,
Mrp2/Abcc2 was immunoprecipitated and immunoblotted as described
in Materials and methods. A pilot experiment is shown. (B) Human
MRP2/ABCC2 was phosphorylated in vitro by recombinant cPKCa,
nPKCe, and PKA in a staurosporine-sensitive way. MRP2/ABCC2 was
immunoprecipitated from human HepG2 hepatoma cells and was
exposed to recombinant cPKCa, nPKCe, and PKA for 2 h in the absence
or presence of the potent PKC inhibitor staurosporine (ST, 10 nmol/l).
MRP2/ABCC2 phosphorylation in the presence of 32P-ATP was
determined radiochemically as described in Materials and methods.
Results are given as means (SD) of three independent preparations.
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post-translational anticholestatic effect mainly by a cooperative
cPKCa-/PKA-dependent mechanism in the experimental model
of TLCA-induced cholestasis.
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